Impact of Ivabradine on Inflammatory Markers in Chronic Heart Failure
Impact of Ivabradine on Inflammatory Markers in Chronic Heart Failure
复制标题
DOI：
10.1155/2016/949320
复制
发表时间：
2016-01-01
影响因子：
4.1
通讯作者：
Yilmaz, Atilla
中科院分区：
文献类型：
--
作者：
Rohm, Ilonka;Kretzschmar, Daniel;Yilmaz, Atilla
背景炎症在慢性心力衰竭（CHF）的进展中起着至关重要的作用。已知伊伐布雷定可降低某些条件下CHF患者的发病率和死亡率。除了降低心率外，关于伊伐布雷定的潜在抗炎作用（可能有助于其在CHF中获益）的知识有限。因此，本研究旨在研究伊伐布雷定对全身性炎症的影响。方法.在本研究中，33例扩张型、缺血性和高血压性心肌病所致CHF患者根据欧洲心脏病学会（ESC）指南接受伊伐布雷定治疗。在伊伐布雷定治疗前和治疗期间，分别使用FACS分析和ELISA研究了大量循环树突状细胞以及炎症介质。结果伊伐布雷定治疗导致CHF症状显著改善以及左心室射血分数增加。此外，伊伐布雷定治疗导致TNF-α（TNF-α）血清水平显著降低和循环树突状细胞重建，已知CHF患者的循环树突状细胞减少。结论我们发现，CHF患者接受伊伐布雷定治疗可改善HF症状和射血分数，并使炎症介质正常化。
Background. Inflammation plays a crucial role in the progression of chronic heart failure (CHF). Ivabradine is known to reduce the morbidity and mortality of patients with CHF under certain conditions. Beyond the reduction of heart rate, only limited knowledge exists about potential anti-inflammatory effects of ivabradine that might contribute to its benefit in CHF. Thus, the present study aimed to investigate the effect of ivabradine on systemic inflammation. Methods. In the present study, 33 patients with CHF due to dilated, ischemic, and hypertensive cardiomyopathy were treated with ivabradine according to the guidelines of the European Society of Cardiology (ESC). A number of circulating dendritic cells as well as inflammatory mediators were investigated using FACS analysis and ELISA, respectively, before and during ivabradine therapy. Results. Treatment with ivabradine resulted in a significant improvement of CHF symptoms as well as an increase in left ventricular ejection fraction. Moreover, ivabradine treatment led to a significant reduction of TNF-alpha (TNF-alpha) serum levels and a reconstitution of circulating dendritic cells which are known to be reduced in patients with CHF. Conclusion. We show that treatment with ivabradine in patients with CHF resulted in an improvement of HF symptoms and ejection fraction as well as a normalization of inflammatory mediators.